AbbVie will report its Q3 2026 earnings before market open on October 30, with shares up 28.55% year to date. Options pricing suggests a roughly 5% price move around the release, indicating high expectations. The company recently trimmed its full-year EPS guidance slightly due to the Apogee Therapeutics acquisition but raised revenue guidance. Key growth drivers include strong sales from Skyrizi and Rinvoq, FDA approvals for new treatments, and positive Phase 3 results for lutikizumab. Analysts expect EPS to roughly double year-over-year, with revenue growth around 10%. Investors will watch for confirmation of the Apogee deal closing, operational performance, and guidance updates to sustain the rally.
AbbVie shares trade at USD 286.00 on Pluang as of Oct 26, 2026 19:01 WIB, just below their 52-week high of USD 289.00, showing resilience with a modest 0.13% gain on the day. The stock's dividend yield stands at 2.42%, complementing its strong year-to-date performance. This trading context highlights investor interest ahead of the upcoming Q3 earnings report and the anticipated price move suggested by options pricing.
The FDA has approved a new subcutaneous induction regimen for SKYRIZI (risankizumab-rzaa) to treat adults with moderately to severely active Crohn's disease. This allows patients to start treatment at home using an on-body injector (OBI) device, impr...
Johnson & Johnson reported strong pharmaceutical growth with Innovative Medicine up 7.9%, driving optimism for its stock with a 12-month price target of $288.66, an 11.48% upside. However, its MedTech segment showed weak international sales growth an...
AbbVie announced positive Phase 3 INTREPID study results for lutikizumab, a dual IL-1α/1β antagonist, in treating moderate to severe hidradenitis suppurativa (HS). The study met its primary endpoint with 31.4% of patients achieving HiSCR75 at Week 16...
